Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Compare
Compare
Traded in other countries / regions
ATAI.USA9VC.GermanyATAI.Mexico IPO Date
2021-06-18Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.54 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.25 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.46 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -157.9 | |||||
3-Year EPS without NRI Growth Rate | -178.3 | |||||
3-Year FCF Growth Rate | -135.2 | |||||
3-Year Book Growth Rate | 59.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.92 | |||||
9-Day RSI | 37.99 | |||||
14-Day RSI | 39.96 | |||||
6-1 Month Momentum % | -33.67 | |||||
12-1 Month Momentum % | -55.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.96 | |||||
Quick Ratio | 10.96 | |||||
Cash Ratio | 10.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | -5.62 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -38764.97 | |||||
Net Margin % | -20043.11 | |||||
FCF Margin % | -27981.14 | |||||
ROE % | -26.44 | |||||
ROA % | -22.46 | |||||
ROIC % | -429.23 | |||||
ROC (Joel Greenblatt) % | -3787.98 | |||||
ROCE % | -24.36 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1060.27 | |||||
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 0.67 | |||||
EV-to-EBIT | 0.17 | |||||
EV-to-Forward-EBIT | -0.04 | |||||
EV-to-EBITDA | 0.17 | |||||
EV-to-Forward-EBITDA | -0.04 | |||||
EV-to-Revenue | -34.05 | |||||
EV-to-Forward-Revenue | 207.74 | |||||
EV-to-FCF | 0.12 | |||||
Price-to-Net-Current-Asset-Value | 1.02 | |||||
Price-to-Net-Cash | 1.06 | |||||
Earnings Yield (Greenblatt) % | 588.24 | |||||
FCF Yield % | -52.61 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATAI
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.334 | ||
EPS (TTM) ($) | -0.45 | ||
Beta | 0 | ||
Volatility % | 60.43 | ||
14-Day RSI | 39.96 | ||
14-Day ATR ($) | 0.085465 | ||
20-Day SMA ($) | 1.18275 | ||
12-1 Month Momentum % | -55.48 | ||
52-Week Range ($) | 1.05 - 3.65 | ||
Shares Outstanding (Mil) | 166.01 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ATAI Life Sciences NV Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(ATAI)'s stock price today?
The current price of ATAI is $1.07. The 52 week high of ATAI is $3.65 and 52 week low is $1.05.
When is next earnings date of ATAI Life Sciences NV(ATAI)?
The next earnings date of ATAI Life Sciences NV(ATAI) is 2024-03-22 Est..
Does ATAI Life Sciences NV(ATAI) pay dividends? If so, how much?
ATAI Life Sciences NV(ATAI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |